Publications by authors named "Erica Koenig"

Claim this Profile
O
Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.
Craig M McDonald, Perry B Shieh, Hoda Z Abdel-Hamid, Anne M Connolly, Emma Ciafaloni, Erica Koenig

J Neuromuscul Dis· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial.
Laurent Servais, Eugenio Mercuri, Volker Straub, Michela Guglieri, Andreea M Seferian, Erica Koenig

Nucleic Acid Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.
Kathryn R Wagner, Nancy L Kuntz, Erica Koenig, Lilly East, Sameer Upadhyay

Muscle Nerve· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy.
Dominic Scaglioni, Francesco Catapano, Matthew Ellis, Silvia Torelli, Darren Chambers, Erica Koenig

Acta Neuropathol Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
Miroslaw Brys, Laura Fanning, Serena Hung, Aaron Ellenbogen, Natalia Penner, Erica Koenig

Mov Disord· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis